Introduction
DISEASE
Optimal control of COVID-19 as it moves into an endemic state requires that vaccination be extended to all ages to minimize disease overall and, especially, to reduce the social and mental health effects on children and adolescents.We describe herein the data supporting safety, immunogenicity, and efficacy in adolescents aged 12 through 17 years in the PREVENT-19 trial. This analysis covered the precrossover, placebo-controlled period from April 26 to September 27, 2021, during which a predominance of the SARS-CoV-2 Delta variant was reported in the US (